Department of Clinical Microbiology, Næstved Hospital, Region Zealand, Næstved, Denmark.
BMC Infect Dis. 2010 Nov 1;10:317. doi: 10.1186/1471-2334-10-317.
Serological testing for Lyme borreliosis (LB) is frequently requested by general practitioners for patients with a wide variety of symptoms.
A survey was performed in order to characterize test utilization and clinical features of patients investigated for serum antibodies to Borrelia burgdorferi sensu lato. During one calendar year a questionnaire was sent to the general practitioners who had ordered LB serology from patients in three Danish counties (population 1.5 million inhabitants). Testing was done with a commercial ELISA assay with purified flagella antigen from a Danish strain of B. afzelii.
A total of 4,664 patients were tested. The IgM and IgG seropositivity rates were 9.2% and 3.3%, respectively. Questionnaires from 2,643 (57%) patients were available for analysis. Erythema migrans (EM) was suspected in 38% of patients, Lyme arthritis/disseminated disease in 23% and early neuroborreliosis in 13%. Age 0-15 years and suspected EM were significant predictors of IgM seropositivity, whereas suspected acrodermatitis was a predictor of IgG seropositivity. LB was suspected in 646 patients with arthritis, but only 2.3% were IgG seropositive. This is comparable to the level of seropositivity in the background population indicating that Lyme arthritis is a rare entity in Denmark, and the low pretest probability should alert general practitioners to the possibility of false positive LB serology. Significant predictors for treating the patient were a reported tick bite and suspected EM.
A detailed description of the utilization of serology for Lyme borreliosis with rates of seropositivity according to clinical symptoms is presented. Low rates of seropositivity in certain patient groups indicate a low pretest probability and there is a notable risk of false positive results. 38% of all patients tested were suspected of EM, although this is not a recommended indication due to a low sensitivity of serological testing.
莱姆病(LB)的血清学检测常由全科医生为具有各种症状的患者提出。
为了描述用于检测血清抗伯氏疏螺旋体的患者的检测利用情况和临床特征,我们进行了一项调查。在一个日历年内,我们向在丹麦三个县(150 万居民)的患者开具 LB 血清学检查的全科医生发送了一份调查问卷。检测使用的是一种基于丹麦一株伯氏疏螺旋体的纯化鞭毛抗原的商业 ELISA 检测试剂盒。
共有 4664 名患者接受了检测。IgM 和 IgG 的血清阳性率分别为 9.2%和 3.3%。有 2643 名(57%)患者的问卷可供分析。38%的患者疑似为游走性红斑(EM),23%疑似为莱姆关节炎/播散性疾病,13%疑似为早期神经莱姆病。0-15 岁年龄和疑似 EM 是 IgM 血清阳性的显著预测因素,而疑似匐行疹则是 IgG 血清阳性的预测因素。关节炎患者中有 646 人疑似 LB,但仅有 2.3%的 IgG 血清阳性。这与背景人群的血清阳性率相当,表明莱姆关节炎在丹麦是一种罕见疾病,低的先验概率应使全科医生警惕 LB 血清学检测可能出现的假阳性。治疗患者的显著预测因素是报告的蜱叮咬和疑似 EM。
本文详细描述了莱姆病血清学检测的利用情况,并根据临床症状列出了血清阳性率。某些患者群体的低血清阳性率表明先验概率较低,存在显著的假阳性结果风险。尽管由于血清学检测的敏感性较低,EM 并不是推荐的检测指征,但接受检测的所有患者中有 38%被怀疑患有 EM。